跳至主要内容
临床试验/NCT04746222
NCT04746222Unknown2 期

Oral Capsule-administered Faecal Microbiota Transplantation for Intestinal Carbapenemase-producing Enterobacteriaceae Decolonization

Tan Tock Seng Hospital0 个研究点目标入组 108 人开始时间: 2021年7月1日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
108
主要终点
Proportion of patients successfully decolonised of CPE intestinal carriage at 12 weeks.

研究概览

简要总结

Double-blinded, randomised controlled trial to evaluate the clinical efficacy of a single dose of oral capsule-administered faecal microbiota transplantation (FMT) for carbapenemase-producing Enterobacteriaceae (CPE) intestinal decolonisation compared with placebo. Primary outcome is the proportion of patients successfully decolonised of CPE intestinal carriage at 12 weeks after FMT treatment compared with placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Study subjects will be randomised to either FMT-capsules or placebo (subject and investigator-blinded) immediately prior to capsule administration. Subjects who are randomised to FMT by capsule will receive 30 FMT-containing capsules under direct-observed therapy. Subjects who are randomised to placebo capsules will receive 30 placebo capsules under direct-observed therapy.

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Admitted as inpatient at the study site at the time of screening.
  • Aged ≥21 years at the time of screening.
  • Sufficiently ambulant to return for outpatient clinic study visit.
  • Detection of CPE (result reported by clinical microbiology laboratory).
  • Ability to provide informed consent.
  • Females of childbearing potential who are sexually active with a non-sterilised male partner must agree to use at least one method of effective contraception for the duration of the trial.
  • Colonisation of the gastrointestinal tract with CPE, confirmed by at least one positive rectal swab taken ≤7 days before randomisation (direct PCR testing using Xpert Carba-R, performed by study team independent of the hospital screening protocol).
  • Ability to swallow "safety test" capsule (one test capsule given during pre-randomisation evaluation).
  • Antibiotics ceased for at least 48 hours before pre-randomisation evaluation.
  • Negative urine pregnancy test for pre-menopausal women taken ≤7 days before randomisation

排除标准

  • Presence of acute diarrhoeal illness (e.g. gastroenteritis, C. difficile colitis) or chronic diarrhoeal illness (e.g. irritable bowel syndrome or inflammatory bowel disease, unless they are in remission for at least 3 months prior to enrolment).
  • Current use or planned use of an investigational drug within 3 months of enrolment.
  • Presence of significant immunosuppression, including but not limited to: use of monoclonal antibody, use of prolonged steroids equivalent to prednisolone dose of ≥20mg/day for ≥28 days, solid organ transplantation, bone marrow transplantation, HIV infection with CD4 count of ≤200, bone marrow transplant, ongoing chemotherapy or radiation therapy, and congenital immunodeficiency.
  • Oropharyngeal dysphagia, significant oesophageal dysphagia, or other inability to swallow.
  • History of surgery altering gastrointestinal anatomy (e.g. colostomy, colectomy).
  • Ileus or small bowel obstruction.
  • Risk of aspiration.
  • History of gastroparesis.
  • Severe food allergy (anaphylaxis or anaphylactoid reaction).
  • Adverse event attributable to previous FMT.
  • Those who are pregnant or plan to be pregnant within 3 months of enrolment.
  • Those who are breastfeeding or plan to breastfeed during the trial.
  • Life expectancy <3 months.

结局指标

主要结局

Proportion of patients successfully decolonised of CPE intestinal carriage at 12 weeks.

时间窗: 12 weeks

Decolonisation is determined by the following test outcomes: i. Negative PCR result (CP genes undetected) for rectal swab sample subjected to direct PCR (Xpert Carba-R) ii. Negative PCR result (CP genes undetected) for rectal swab sample subjected to culture on ChromID CARBA SMART media followed by PCR for suspected CPE colonies (Xpert Carba-R) iii. Negative PCR result (CP genes undetected) for stool sample subjected to direct PCR (Xpert Carba-R) iv. Negative PCR result (CP genes undetected) for stool sample subjected to culture on ChromID CARBA SMART media followed by PCR for suspected CPE colonies (Xpert Carba-R) At least two of the four tests must be evaluable (clear positive or negative result obtained). Subject not meeting these criteria will be considered not-decolonised. If any one of the PCR results are positive, the subject is considered not-decolonised.

次要结局

  • Progression to CPE infection(Up to 48 weeks)
  • Proportion of patients successfully decolonised of CPE intestinal carriage at 1, 2, 6, 24, 36 and 48 weeks.(1, 2, 6, 24, 36 and 48 weeks)
  • Changes in stool microbiome(1, 2, 6, 12, 24, 36, and 48 weeks)
  • Frequency and severity of adverse events(Up to 48 weeks)

研究者

发起方
Tan Tock Seng Hospital
申办方类型
Other
责任方
Sponsor

相似试验